Cyclo Therapeutics- Warrants (14/11/2025) Overview
Valuation check: CYTHW's P/E ratio is -0.59, below the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow-0.59
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for CYTHW is -0.59. That is below the Healthcare sector average of 25.3. Investors often review this figure alongside Cyclo Therapeutics- Warrants (14/11/2025)'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CYTHW currently prints -0.59 for P/E ratio, while the sector average sits near 25.3. That is roughly 102.3% below the sector mean. Large gaps often invite a closer look at Cyclo Therapeutics- Warrants (14/11/2025)'s growth, margins, and balance sheet.
A P/E ratio of -0.59 for Cyclo Therapeutics- Warrants (14/11/2025) is not 'good' or 'bad' on its own. Compare it with the peer average (25.3) and with CYTHW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CYTHW's P/E ratio (-0.59), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Cyclo Therapeutics- Warrants (14/11/2025)'s P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
